Application of mTOR inhibitors in UBC treatments should depend on careful selection of the tumor type: NMIUBC seems to respond to combination of rapalogs and other drugs, while only those MIUBC patients with phosphorylated mTOR are suitable to accept mTOR inhibitors treatments. Here, MTOR is linked to neoplasm.